ライフサイエンスコーパス: pneumonia

1 nts with coronavirus disease 2019 (COVID-19) pneumonia.

2 d specific policies on use of CT in COVID-19 pneumonia.

3 egnant adult patients who developed COVID-19 pneumonia.

4 rted that occurred after onset of aspiration pneumonia.

5 athogens in patients with community-acquired pneumonia.

6 ia or be associated with secondary bacterial pneumonia.

7 liferate within alveolar macrophages causing pneumonia.

8 vasculitis was detected in mice with severe pneumonia.

9 pe pneumococcal pneumonia or nonpneumococcal pneumonia.

10 (systolic arterial pressure <=90 mm Hg), and pneumonia.

11 inst community-detected cases of RSV-ILI and pneumonia.

12 ents with COVID-19 to prevent progression to pneumonia.

13 mining the clinical prognosis for SARS-CoV-2 pneumonia.

14 rison with healthy controls and non-COVID-19 pneumonia.

15 ore was calculated to assess the severity of pneumonia.

16 sis and rendered newborn mice susceptible to pneumonia.

17 rment, asthma, and a history with bronchitis/pneumonia.

18 iratory failure associated with Pneumocystis pneumonia.

19 ated with higher mortality from influenza or pneumonia.

20 ens in patients with a clinical diagnosis of pneumonia.

21 siblings died around 2-3 years of age due to pneumonia.

22 ement in coronavirus disease 2019 (COVID-19) pneumonia.

23 g the definition of radiologically confirmed pneumonia.

24 ng infections, including COVID-19-associated pneumonia.

25 whereas IPF is defined by usual interstitial pneumonia.

26 for pathogenesis in a murine model of acute pneumonia.

27 n of corticosteroids in patients with severe pneumonia.

28 al-related infections, especially nosocomial pneumonia.

29 ae is a common cause of antibiotic-resistant pneumonia.

30 per annum, with 7% of these attributable to pneumonia.

31 e available for pregnant women with COVID-19 pneumonia.

32 or severe COVID-19 disease died of bacterial pneumonia.

33 ction of Coronavirus Disease 2019 (COVID-19) pneumonia.

34 ng blood transfusions, thrombocytopenia, and pneumonia.

35 Nine patients developed COVID-19 pneumonia.

36 ic interventions for patients with bacterial pneumonia.

37 t radiograph reading score 2 as positive for pneumonia.

38 and a fifth fewer deaths due to malaria and pneumonia.

39 cificity in predicting outcome of SARS-CoV-2 pneumonia.

40 graphs in patients with and without COVID-19 pneumonia.

41 of COVID-19 with high fever and severe viral pneumonia.

42 responses, and pathologic evidence of viral pneumonia.

43 nt and increases susceptibility to secondary pneumonia.

44 oniae is a major cause of community-acquired pneumonia.

45 Staphylococcus aureus is a leading cause of pneumonia.

46 ic perfusion patterns are common in COVID-19 pneumonia.

47 , meningitis (0.67, 0.46-0.97; p=0.036), and pneumonia (0.83, 0.68-1.00; p=0.051).

48 in >=5% of patients) were neutropenia (14%), pneumonia (11%), hypertension (7%), anemia (7%), and dia

49 Most common complications were pneumonia (12%), esophago-enteric leak from anastomosis,

50 d incidence density of ventilator-associated pneumonia (2.4/1,000 patient-days vs 0.6/1,000 patient-d

51 o [1%]), anaemia (31 [16%] vs 20 [10%]), and pneumonia (22 [11%] vs 22 [11%]).

52 91]), shock at onset (4.62 [2.49-8.56]), and pneumonia (3.01 [1.55-5.83]).

53 $156 per DALY), malaria ($125 per DALY), and pneumonia ($33 per DALY).

54 ients (276/315, 88%) recovered from COVID-19 pneumonia; 36/315 patients (11%) died, and 3/315 patient

55 (6.5%) and the condition-based diagnosis of pneumonia (4.1%).

56 trates more often had a primary diagnosis of pneumonia (41% vs 28%; p = 0.02) and less often asthma (

57 For pneumonia, 63.1% of overuse days after discharge were du

58 ses were prevalent (all >30%); 66% developed pneumonia, 80% of which were radiographically confirmed.

59 ous ability of chronic SCI rats to fight off pneumonia, a common cause of hospitalization after injur

60 ity of chronically injured rats to fight off pneumonia, a common cause of hospitalization.

61 pneumoniae virulence factors needed to cause pneumonia, a high-throughput screen was performed with a

62 ug resistant and cause healthcare-associated pneumonia, a major risk factor for acute lung injury (AL

63 ic, resulting from SARS-CoV-2, induces acute pneumonia, a phenotype that is alarmingly increased with

64 Culture-negative pneumonia accounted for 61% of cases and was significant

65 Pneumonia, acute chronic obstructive pulmonary disease/a

66 acterized by atypical interstitial bilateral pneumonia, acute respiratory distress syndrome and multi

67 ificant driver of both primary and secondary pneumonia among children.

68 standard deviation]; 1059 men) with COVID-19 pneumonia and 3148 patients (5300 chest radiographs; mea

69 ined as PPV23 serotype-specific pneumococcal pneumonia and a control as non-PPV23 serotype pneumococc

70 Obesity is a risk factor for pneumonia and acute respiratory distress syndrome.

71 radiologists recognize findings of COVID-19 pneumonia and aid their communication with other health

72 tial virus (RSV) is a leading cause of viral pneumonia and bronchiolitis during the first six months

73 that vary from asymptomatic cases to severe pneumonia and death.

74 Culture-proven aspiration pneumonia and early-onset ventilator-associated pneumoni

75 ified as having likely or unlikely bacterial pneumonia and followed for outcome assessment.

76 to examine the relationships between fungal pneumonia and FOXA2-regulated airway mucus homeostasis.

77 Midwestern regions had the highest rates of pneumonia and influenza from 2013 to 2015.

78 alization [i.e., all-cause, respiratory, and pneumonia and influenza, (P&I)].

79 6 months of age and visited weekly to detect pneumonia and influenza-like illness.

80 atremia occurs in up to 30% of patients with pneumonia and is associated with increased morbidity and

81 Klebsiella pneumoniae causes pneumonia and liver abscesses in humans worldwide and co

82 vere patients with COVID-19 hospitalized for pneumonia and longitudinally followed for the developmen

83 shown to initiate and maintain responses to pneumonia and lung inflammation, often playing a role in

84 Severe pneumonia and multiorgan dysfunction in COVID-19 and den

85 aths and reduced coverage of antibiotics for pneumonia and neonatal sepsis and of oral rehydration so

86 ree deaths in the venetoclax group (two from pneumonia and one from septic shock) were considered tre

87 p) is the etiological agent of acute porcine pneumonia and responsible for severe economic losses wor

88 atients with chronic lung disease, can cause pneumonia and sepsis and can trigger exacerbations of lu

89 and diarrhea and can end up in interstitial pneumonia and severe respiratory failure.

90 entilation were more likely to have comorbid pneumonia and severe sepsis.Conclusions: Noninvasive ven

91 r starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed afte

92 ng imaging features consistent with COVID-19 pneumonia and symptoms.

93 One week later, she was hospitalised with pneumonia and tested positive for SARS-CoV-2.

94 ho developed influenza-like-illness (ILI) or pneumonia and were RSV positive by PCR.

95 e to malaria, 252 (16.1%) deaths were due to pneumonia, and 234 (14.9%) deaths were due to diarrhoea.

96 s 25.4%, p = 4.4 x 10 for community-acquired pneumonia, and 7.1% vs 20.0%, p = 3.4 x 10 for abdominal

97 on hemodialysis, who presented with COVID-19 pneumonia, and despite completing a 5-day course of hydr

98 al cause of bacterial middle ear infections, pneumonia, and meningitis.

99 Anastomotic leakage, pneumonia, and other postoperative complications did not

100 ndary outcomes included anastomotic leakage, pneumonia, and other surgical complications.

101 tients had higher rates of death, infection, pneumonia, and postoperative stroke compared to White pa

102 Chest radiography showed no pneumonia, and venous ultrasonography of both legs showe

103 occus aureus is a leading cause of bacterial pneumonia, and we have shown previously that type I inte

104 spontaneous bacteria peritonitis (SBP), and pneumonia; and O: the CLIF consortium organ failure scor

105 admission to a health facility, diagnosis of pneumonia, antibiotic use, or respiratory or gastrointes

106 Patients with moderate-to-severe COVID-19 pneumonia are likely to benefit from moderate-dose corti

107 Advanced age and pneumonia are the main clinical features associated with

108 pulations who are hospitalized with Covid-19 pneumonia are unclear.

109 hospital-acquired and ventilator-associated pneumonia, are common in hospitalized patient population

110 emerged causing an ongoing outbreak of viral pneumonia around the world.

111 al prognostic cutoffs for burden of COVID-19 pneumonia as determined by Youden's index were consolida

112 ing clinical signs to identify children with pneumonia at high risk of mortality in the outpatient se

113 The existing definitions of pneumonia based on hospital acquired pneumonia (HAP) cla

114 te prediction model of outcome of SARS-CoV-2 pneumonia based on laboratory findings.

115 As an atypical pneumonia began to appear in December 2019, Zhou et al.

116 y reduced by 39% (95% CI 5-62) for all-cause pneumonia, bronchiolitis, and asthma admissions in child

117 in the first 7 postoperative days, including pneumonia, bronchospasm, atelectasis, pulmonary congesti

118 hypercoagulable phenotype in severe COVID-19 pneumonia but also markedly impaired pulmonary perfusion

119 cant declines in community-acquired alveolar pneumonia (CAAP) and overall chest radiography examinati

120 Community-acquired bacterial pneumonia (CABP) remains a significant cause of morbidit

121 In this setting, using the term viral pneumonia can be a reasonable and inclusive alternative.

122 ospitalized patients with community-acquired pneumonia (CAP) and performed a comprehensive screen for

123 the diverse etiologies of community-acquired pneumonia (CAP) and the limitations of current diagnosti

124 Society of America (IDSA) Community-acquired Pneumonia (CAP) guidelines were developed using systemat

125 ive tuberculosis, 100 had community-acquired pneumonia (CAP), 26 had P. jirovecii pneumonia (PJP), an

126 ococcal disease (IPD) and community-acquired pneumonia (CAP), it is unclear whether this remains the

127 of attenuating mouse mortality during acute pneumonia caused by both group 1 and group 2 S. pneumoni

128 te the cytokine storm associated with severe pneumonia caused by coronaviruses.

129 A trend was observed among pneumonias caused by nonfermenting gram-negative bacilli

130 diagnosis code for urinary tract infection, pneumonia, cellulitis/osteomyelitis, or bacteremia/septi

131 severely affected patients includes atypical pneumonia characterized by a dry cough, persistent fever

132 creased virulence in a murine model of acute pneumonia compared to USA300 (current epidemic strain an

133 with hospital-acquired/ventilator-associated pneumonia, complicated intraabdominal infection, or comp

134 Pneumonia constitutes a substantial disease burden among

135 Among those who met WHO pneumonia criteria, 8.6% (189/2199) experienced an adver

136 complications such as ventilator-associated pneumonia, deep vein thrombosis, and pressure sores; and

137 f regulator DprA was highly expressed during pneumonia-derived sepsis but failed to turn off the comp

138 so able to develop natural competence during pneumonia-derived sepsis.

139 nt state was prolonged and persistent during pneumonia-derived sepsis.

140 e competence development in a mouse model of pneumonia-derived sepsis.

141 Regarding pneumonia detection, radiologists achieved a maximum dia

142 23-year old, asthmatic male with coronavirus pneumonia developed with generalized, acute abdominal pa

143 eases, stroke, cancer, asthma, influenza and pneumonia, diabetes, and HIV/AIDS.

144 In resource-limited settings, pneumonia diagnosis and management are based on threshol

145 in delivery, 10% (95% CI, 8%-12%) included a pneumonia diagnosis, 5% (95% CI, 3%-6%) required intensi

146 aspiration is the gold standard specimen for pneumonia diagnostics.

147 Pneumonia did not impact on overall survival (P=0.807).

148 disease and pneumococcal community-acquired pneumonia differed by age and between Indigenous and non

149 d as the causal agent for the pandemic viral pneumonia disease, COVID-19.

150 lth (PERCH) study with severe or very severe pneumonia during 2011-2014 were used to build a parsimon

151 e factors associated with severe bacteraemic pneumonia during serotype-1 (ST217) infection.

152 alizations, and N = 113 997 culture-negative pneumonia ED visits included in our analyses.

153 Pulse oximetry identified fatal pneumonia episodes at HCs in Malawi that would otherwise

154 ve children aged 1-59 months enrolled in the Pneumonia Etiology Research for Child Health (PERCH) stu

155 ng it an optimal resource for determining Mp pneumonia etiology.

156 % accuracy with LASSO in predicting specific pneumonia etiology.

157 ronavirus disease 2019 (COVID-19)-associated pneumonia evolve toward severe oxygen dependence (stage

158 COVID-19 pneumonia exhibits several extra-pulmonary complications

159 Pacific region to show the effect of PCV on pneumonia, filling gaps in the literature on the effects

160 piratory complications, including aspiration pneumonia, fistula and airway compression.

161 monia or death among patients with bacterial pneumonia following clinical cure.

162 dence remains sparse and the risk period for pneumonia following influenza poorly defined.

163 ED) visits for influenza or culture-negative pneumonia from 2005 to 2016.

164 Adult patients admitted with a diagnosis of pneumonia from 2012 to 2014 were included.

165 lication, further detection of Streptococcus pneumonia from 50 to 5x10(4) CFU/mL were successfully pe

166 lligence algorithm to differentiate COVID-19 pneumonia from other causes of abnormalities at chest ra

167 eatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoan

168 ions of pneumonia based on hospital acquired pneumonia (HAP) classifications may be suboptimal in thi

169 dherence to guidelines for hospital-acquired pneumonia (HAP) for can improve the outcomes of patients

170 In the era of prophylaxis, Pneumocystis pneumonia has become a late-onset opportunistic infectio

171 While the association with secondary pneumonia has been established ecologically, individual-

172 ciaries admitted to US CAHs and non-CAHs for pneumonia, heart failure, chronic obstructive pulmonary

173 a time-series analysis assessing changes in pneumonia hospital admissions at three public tertiary h

174 adiographically confirmed community-acquired pneumonia hospitalizations among children and adults in

175 ions for influenza, but not culture-negative pneumonia hospitalizations or ED visits.

176 enza ED visits, N = 274 226 culture-negative pneumonia hospitalizations, and N = 113 997 culture-nega

177 ded the initial evidence of COVID-19-related pneumonia in 32 of 62 (52%) patients.

178 italized adult patients with severe Covid-19 pneumonia in a 2:1 ratio to receive convalescent plasma

179 air quality and risk of hospitalization for pneumonia in adults in China.

180 causing bronchitis and atypical or "walking" pneumonia in humans.

181 ment with antibiotic agents in children with pneumonia in low-resource settings in Africa is lacking.

182 and in-hospital case-fatality ratio (CFR) of pneumonia in older adults, stratified by age and economi

183 eosinophils, ICS treatment, and the risk of pneumonia in patients with COPD.Methods: This was a post

184 The clinical characteristics of COVID-19 pneumonia in pregnant women were similar to those report

185 ith influenza had greater risk of developing pneumonia in the 30 days following onset compared to tho

186 ss and decreases lung titers and evidence of pneumonia in the lungs.

187 critical for lung defense against bacterial pneumonia in the neonatal period, but the signals that g

188 adverse events in more than one patient were pneumonia (in five [29% patients); tumor lysis syndrome

189 nd 15 patients (6.5%), respectively (overall pneumonia incidence, 29.9%).

190 health outcomes are low birth weight, severe pneumonia incidence, stunting in the child, and high blo

191 ory findings of 110 patients with SARS-CoV-2 pneumonia (including 51 non-survivors and 59 discharged

192 SL) was applied to 31 (47.69%) patients with pneumonia, including 10 (31.25%) general, 8 (100%) sever

193 atients with suspected ventilator-associated pneumonia, including patient groups not previously recog

194 hibited reduced fitness in a murine model of pneumonia, indicating that MumR-regulated gene products

195 bacterial survival in a mouse model of acute pneumonia infection.

196 l, Streptococcus pneumoniae, and unspecified pneumonia); influenza; tuberculosis; and other lower and

197 Pneumonia is a leading cause of mortality worldwide.

198 Pneumonia is commonly documented following esophageal ca

199 ication of coronavirus disease 19 (COVID-19) pneumonia is currently not recommended by most radiology

200 re acute respiratory syndrome corona virus 2 pneumonia is linked to both acute respiratory distress s

201 egories atypical appearance and negative for pneumonia is nonnegligible.Supplemental material is avai

202 As postoperative mortality in case of COVID pneumonia is not negligible, meticulous rules (precise t

203 Pneumonia is the leading cause of antibiotic use and hos

204 oniae is a major cause of community-acquired pneumonia leading to high mortality rates.

205 c pathogen that causes the potentially fatal pneumonia Legionnaires' Disease.

206 lse oximetry use during infant and childhood pneumonia management at the primary healthcare level in

207 s that urine from patients hospitalized with pneumonia may serve as a reliable and accessible sample

208 at admission, confirmed ventilator-assisted pneumonia, median ICU stay, median hospital stay, mortal

209 es of critically ill patients and in a mouse pneumonia model.Methods: Total classical (CH50) and alte

210 a from 52 hospital studies reporting data on pneumonia mortality, we estimated that about 1.1 million

211 nononcologic causes 1-5 years after surgery; pneumonia (n = 21) and myocardial infarction (n = 10) we

212 umococcal conjugate vaccine (PCV13) serotype pneumonia (n = 417 cases, 43.7% vaccinated) was 29% (95%

213 Pneumonia (n=5 [5%]) and lower respiratory tract infecti

214 n serious adverse events were pyrexia (n=9), pneumonia (n=6), and sepsis (n=6).

215 ower respiratory tract infection (n=7 [7%]), pneumonia (n=7 [7%]), pyrexia (n=4 [4%]), cellulitis (n=

216 activation [n=1], and Pneumocystis jirovecii pneumonia [n=1]).

217 umonia should be suspected in any child with pneumonia not responding to appropriate antibiotic treat

218 ase at the expense of increasing the risk of pneumonia.Objectives: To assess the relationship between

219 umonia and early-onset ventilator-associated pneumonia occurred in 54 patients (23.4%) and 15 patient

220 were identified as independent predictors of pneumonia occurrence in the whole study population.

221 predictive value (NPV) for likely bacterial pneumonia of 99.0%.

222 d thyroid carcinoma also showed interstitial pneumonia on SPECT/CT.

223 neutrophils to VD2 (or CD8) T-cells predicts pneumonia onset (0.9071) as well as hypoxia onset (0.890

224 ess common CT appearances include organizing pneumonia or acute eosinophilic pneumonia patterns, the

225 Influenza may result in primary pneumonia or be associated with secondary bacterial pneu

226 was independently associated with recurrent pneumonia or death among patients with bacterial pneumon

227 ne of the patients developed severe COVID-19 pneumonia or died, as of Feb 4, 2020.

228 risk factors for RSV febrile illness and RSV pneumonia or hospitalization.

229 a control as non-PPV23 serotype pneumococcal pneumonia or nonpneumococcal pneumonia.

230 arge among hospitalized patients treated for pneumonia or urinary tract infection (UTI) and determine

231 tion tests (OR 11.19, 95% CI: 2.09-60.02) or pneumonia (OR 5.37, 95% CI: 1.17-24.65), any adverse eve

232 arily affects the lung parenchyma by causing pneumonia, our directive is to focus on thoracic finding

233 f pulmonary opacities in predicting COVID-19 pneumonia outcome, disease severity, and patient triage.

234 ted with atrial fibrillation (P = 0.013) and pneumonia (P = 0.005).

235 ecrosis (P = 0.524), chyle leak (P = 0.427), pneumonia (P = 0.548), and respiratory failure (P = 0.72

236 Preoperative respiratory disease predicted pneumonia (P=0.043).

237 ng independently associated with the risk of pneumonia, particularly when both coexist (HR, 3.126).

238 Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated

239 piratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients indicate that a cytokine storm may in

240 In addition, follow up CT scans from 11 pneumonia patients showed full recovery.

241 mobilization improved ventilator-associated pneumonia patients' Medical Research Council score; redu

242 still have a negative impact on prognosis of pneumonia patients, including higher mortality and prolo

243 ence and severity of respiratory distress in pneumonia patients.

244 Histologically, a nonspecific interstitial pneumonia pattern is commonly observed in SSc-ILD, where

245 e organizing pneumonia or acute eosinophilic pneumonia patterns, the latter consisting of multifocal

246 dard for diagnosis of Pneumocystis jirovecii pneumonia (PCP).

247 cts healthy individuals against Pneumocystis pneumonia (PcP).

248 issions for respiratory disease, asthma, and pneumonia peaked at lag 3 by 8.85% (95% CI: 0.80, 17.55)

249 on when to reinitiate Pneumocystis jirovecii pneumonia (PJP) prophylaxis in solid organ transplant (S

250 cquired pneumonia (CAP), 26 had P. jirovecii pneumonia (PJP), and 64 had other diagnoses.

251 ious AEs were reported (rhinitis [JNJ-8678]; pneumonia [placebo]).

252 National guidelines for pneumonia (PNA), urinary tract infection (UTI), and acut

253 tify acute AF precipitants (surgery, sepsis, pneumonia, pneumothorax, respiratory failure, myocardial

254 - and 90-day mortality; development of ARDS, pneumonia, pneumothorax, severe atelectasis, severe hypo

255 ors with at least one other organ harvested (pneumonia prevalence in lung donors (9.7%) vs nondonors

256 fter successful treatment of donor bacterial pneumonia promotes PGD through ischemia/reperfusion-prim

257 In some mice, acute pneumonia quickly led to sepsis and death, accompanied b

258 uded chest CTs from oncology, emergency, and pneumonia-related indications.

259 healthy individuals with community-acquired pneumonia remains an unmet medical need.

260 respiratory tract illness with high rates of pneumonia, requirement for ventilatory support, and shor

261 any patient with severe disease (eg, ARDS or pneumonia) requiring hospitalization without an explanat

262 ty range [UR], 5.8-8.0 episodes) of clinical pneumonia resulted in hospital admissions of older adult

263 Pneumonia resulting from infection is one of the leading

264 We found no difference between groups in pneumonia, serious infections, any infection, hemorrhage

265 Pneumonia severity scores achieve respective accuracies

266 Complicated community-acquired pneumonia should be suspected in any child with pneumoni

267 nts who proceeded to develop COVID-19 severe pneumonia (SP) and DHF had significantly higher levels o

268 monia using clinical specimens collected for pneumonia surveillance in The Gambia.

269 community-acquired or healthcare-associated pneumonia to 170 US hospitals in the Premier database fr

270 19 includes lung infection ranging from mild pneumonia to life-threatening acute respiratory distress

271 clinical outcome for patients with COVID-19 pneumonia.TRIAL REGISTRATIONClinicalTrials.gov NCT044386

272 sistently elevated IRRs for viral and fungal pneumonias (up to 10.8-fold), meningitis (up to 5.3-fold

273 nvestigated the pathogenesis of pneumococcal pneumonia using clinical specimens collected for pneumon

274 an important cause of ventilator-associated pneumonia (VAP).

275 mycosis; coccidioidomycosis; histoplasmosis; pneumonia (viral, bacterial, Streptococcus pneumoniae, a

276 ents with confirmed coronavirus disease 2019 pneumonia, visual or software quantification of the exte

277 served cases to expected cases for all-cause pneumonia was 0.92 (95% CI 0.70-1.36) for children aged

278 The incidence of RSV pneumonia was 29 cases per 1000 person-years.

279 In multivariable analysis, pneumonia was associated (P<0.05) with respiratory comor

280 Pneumonia was associated with a postadmission decrease i

281 olvement were present in 54 (93%), bilateral pneumonia was present in 53 (91%), and subsegmental vess

282 Pneumonia was the most common infection encountered in b

283 Invasive pneumonia was the most common presentation (11 424/16 34

284 Pneumonia was the only serious adverse event in more tha

285 th laboratory confirmed other (non COVID-19) pneumonias was 10%.

286 64 years +/- 18; 1578 men) with non-COVID-19 pneumonia were included and split into training and vali

287 Cox regression analysis showed that age and pneumonia were independently associated with death, wher

288 Factors predictive of unlikely bacterial pneumonia were no fever, no consolidation on chest radio

289 , which are highly resistant to pneumococcal pneumonia when infected with other serotypes.

290 Streptococcus pneumoniae is a major cause of pneumonia, wherein infection of respiratory mucosa drive

291 hich requires antibiotic therapy, from viral pneumonia, which does not.

292 le the practitioner to distinguish bacterial pneumonia, which requires antibiotic therapy, from viral

293 f adult patients hospitalized with bacterial pneumonia who achieved clinical cure.

294 omatic patients suspected of having COVID-19 pneumonia who underwent both initial chest CT and at lea

295 tly classified chest radiographs as COVID-19 pneumonia with an area under the receiver operating char

296 f age and who met WHO criteria for nonsevere pneumonia with tachypnea were randomly assigned to a 3-d

297 mends oral amoxicillin for patients who have pneumonia with tachypnea, yet trial data indicate that n

298 OVID-19, caused by SARS-CoV-2, is a virulent pneumonia, with >4,000,000 confirmed cases worldwide and

299 of patients suffered one or more episodes of pneumonia, with CBI (hazard ratio [HR], 1.635) and <100

300 of 2055 for AMI, and 724 (24.9%) of 2911 for pneumonia would change if the EDAC measure were used ins